ZNTL

NASD Zentalis Pharmaceuticals, Inc.

Oct 13, 2026 · 12:23 PM ET DELAYED Market Open

$2.45 ↓ -0.08 (-2.98%) Trading Down from the previous close of $2.52, $0.10 below the day’s high of $2.54

YTD change: +81.11%
vs 20-day SMA: -12.26%
vs 200-day SMA: -29.20%

Price ranges

Previous day

$2.51 $2.64

open $2.64 close $2.52

-$0.12 (-4.55%)

Today

$2.44 $2.54

open $2.53 now $2.45

-$0.09 (-3.36%)

Past week

$2.39 $2.82

from $2.78 now $2.45

-$0.34 (-12.05%)

Past month

$2.39 $3.51

from $3.50 now $2.45

-$1.06 (-30.14%)

This year

$1.32 $6.95

from $1.35 now $2.45

+$1.10 (+81.11%)

Price & Performance

-3.04 (-54.68%) / 6M

Signals & Sentiment

Momentum, market sentiment, and recent alerts

Poor

The stock is 97.2% away from all-time highs of $87.19
ZNTL is up 81% since the beginning of the year
ZNTL is up 51% over the past 12 months
ZNTL is down 30% over the past 1 month
6% of all ZNTL investors are betting against ZNTL

ZNTL reads poor: price sits below both the 20- and 200-day averages, the 12-month move is +55.6%.

Financial Strength

Earnings, valuation, and balance sheet

Earnings

Profitable No

EPS $-0.59

Earnings momentum -6.7% Quarterly EPS growth

Quarterly change -6.7%

Valuation

P/E ratio N/A

Enterprise value $42.8M

Beta 2.26

Balance sheet & scale

IncomeN/A

RevenueN/A

Cash$174.6M

Debt$37.7K

Income / Debt N/A

Company & Peers

Company profile and competitor comparison

Company profile

ExchangeNASD

Sector Manufacturing

Sub Sector Chemical Manufacturing

Market cap $231.5M

Zentalis Pharmaceuticals, Inc. is a clinical oncology innovator developing an oral, non-chemotherapy, biomarker-driven treatment approach for ovarian cancer and multiple tumor types. The therapeutics development and biomarker expertise is advancing monotherapy and combination studies of its investigational potential first-in-class WEE1 inhibitor, azenosertib. It is focused on translating WEE1 science into clinical practice, aiming to equip physicians with a targeted, orally available medicine that enhances treatment experience, choice, and outcomes. The company was founded by Kevin D. Bunker and Cam Gallagher on December 23, 2014 and is headquartered in San Diego, CA.

Competitor comparison

Ticker	Company	Price	Change
LLY	Eli Lilly and Company	$1,182.62	+0.28%
JNJ	Johnson & Johnson	$263.73	+0.88%
ABBV	AbbVie, Inc.	$281.12	+1.68%
MRK	Merck & Co., Inc.	$145.45	-0.10%
RHHBY	Roche Holding Ltd Sponsored ADR	$54.10	+0.02%

You looked up one stock
Trade Ideas watches them all

Real-time scanning and AI-generated signals across the entire market.

See plans TI Pro Download

Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.